Contents hide 1 Type 1 Neurofibromatosis 1.1 ≥2 years 1.2 Recommended dosage based on BSA 2 Dosage Modifications 2.1 Dose reductions for adverse reactions based on BSA 2.1.1 First dose reduction 2.1.2 Second dose reduction 2.1.3 Subsequent dose reductions 2.2 Cardiomyopathy 2.3 Ocular toxicity 2.4 Gastrointestinal toxicity 2.5 Skin toxicity 2.6 Increased creatine phosphokinase (CPK) 2.7 Other adverse reactions 2.8 Dosage modifications for drug interactions 2.8.1 Strong or moderate CYP3A4 inhibitors or fluconazole 2.8.2 Dosage reduction to 20 mg/m2 based on BSA 2.8.3 Dosage reduction to 15 mg/m2 based on BSA 2.9 Renal impairment 2.10 Hepatic impairment 2.11 Moderate (Child-Pugh … Continue reading SEMEDX 25 (Selumetinib)